Chapter 72 Chapter 72 Calcium in the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.

Slides:



Advertisements
Similar presentations
Chapter 68 Chapter 68 Fracture Risk Assessment: The Development and Application of FRAX ® Copyright © 2013 Elsevier Inc. All rights reserved.
Advertisements

Chapter 31 Chapter 31 Clinical and Epidemiological Studies: Skeletal Changes across Menopause Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 85 Chapter 85 Parathyroid Hormone Treatment for Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 41 Chapter 41 Bone Mineral Acquisition in Utero and During Infancy and Childhood Copyright © 2013 Elsevier Inc. All rights reserved.
A Comparison of the Effectiveness of Estrogen-Progesterone and Estrogen-Testosterone Combination Therapies in the Prevention of Osteoporosis in Postmenopausal.
Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 83 Chapter 83 Denosumab for the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 28 Chapter 28 Nutrition and Risk for Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 54 Chapter 54 HIV and Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.
Therapeutic Implications
From: Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis Ann Intern.
Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis  Peyman Hadji  Critical Reviews in Oncology.
Algorithm of the approach to the diagnosis and treatment of children with fractures due to osteoporosis. BMD, bone mineral density; GC, glucocorticoids;
A. Mean difference in the lumbar spine areal BMD Z-score in published, controlled trials of bisphosphonate therapy for the treatment of children with osteoporosis,
Calcium balance and fluxes in a normal human
Fig. 1. Trial profile. From: Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the.
Modeling Constraints with Parametrics
The Gutsy Side of Bone Cell Metabolism
Copyright © 2016 Elsevier Inc. All rights reserved.
Skeletal Morbidity in Men with Prostate Cancer: Quality-of-Life Considerations throughout the Continuum of Care  Fred Saad, Carl Olsson, Claude C. Schulman 
Chapter 65 - The Hormonal Regulation of Calcium Metabolism
Copyright © 2012, Elsevier Inc. All rights Reserved.
Chapter 11.
Volume 76, Pages S50-S99 (August 2009)
Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright © 2012, Elsevier Inc. All rights Reserved.
Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright © 2012, Elsevier Inc. All rights Reserved.
Chapter 10.
Chapter 28 - Renal Hyperplasia and Hypertrophy
Copyright © 2012, Elsevier Inc. All rights Reserved.
Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright © 2013 Elsevier Inc. All rights reserved.
Cancer Treatment-Induced Bone Loss (CTIBL) in Prostate Cancer: Pathophysiology, Preclinical Findings, and Treatment with Zoledronic Acid  Theresa A. Guise,
Copyright © 2013 Elsevier Inc. All rights reserved.
Modeling Cross-Cutting Relationships with Allocations
Portable Biotechnology
© 2012 Elsevier, Inc. All rights reserved.
Modeling Text-Based Requirements and their Relationship to Design
Modeling Functionality with Use Cases
Customizing SysML for Specific Domains
Copyright © 2012, Elsevier Inc. All rights Reserved.
Chapter 91 Epidemiology of Headache in Women:
Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 12.
Chapter 6.
Copyright © 2012, Elsevier Inc. All rights Reserved.
© 2012 Elsevier, Inc. All rights reserved.
Chapter 103 Long-Term Care: The Global Impact
Chapter 01.
Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 08.
Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 64 - Renal Calcium Metabolism
Randomized Controlled Trial of Calcium in Healthy Older Women
© 2015 Elsevier, Inc. All rights reserved.
Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright © 2012, Elsevier Inc. All rights Reserved.
Chapter 15 Contraception
Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 15.
Chapter 77 Cervical Cancer: Burden of Disease
Chapter 20 Assisted Reproductive Technologies
Chapter 3.
© 2015 Elsevier, Inc. All rights reserved.
Presentation transcript:

Chapter 72 Chapter 72 Calcium in the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.

FIGURE 72.1 The time course of fracture events (panel A) and the change in bone mineral density at the hip (Panel B) in a trial of calcium supplementation in 3270 healthy, elderly French women [6]. By 18 months of calcium supplementation, hip fracture risk had been reduced and the bone loss occurring in the placebo group had been stopped (and to some extent reversed). Source: redrawn from the data in the paper of Chapuy et al. [6]; Copyright Robert P. Heaney, Reproduced with permission. 2

Copyright © 2013 Elsevier Inc. All rights reserved. FIGURE 72.2 Time course of hip bone mineral density (BMD) in the treated and control groups of the trial by Chapuy et al. [6]. The solid lines represent the data to the end of study, and the dashed lines, their likely extension for a further 18 months. Source: Copyright Robert P. Heaney, Reproduced with permission. 3

Copyright © 2013 Elsevier Inc. All rights reserved. FIGURE 72.3 Time course of fracture events in the trial of Dawson-Hughes et al. [7]. The solid circles are for the controls and the open circles for the calcium-treated group. The dashed lines represent the trend lines for the two contrast groups. Source: redrawn from the original data; Copyright Robert P. Heaney, Reproduced with permission. 4

Copyright © 2013 Elsevier Inc. All rights reserved. FIGURE h, overnight time course of serum Ca and parathyroid hormone (PTH) in untreated controls and in patients receiving alendronate [21]. Solid circles are for the untreated control group and the open circles for the alendronate-treated group. Source: Copyright Robert P. Heaney, Reproduced with permission. 5

Copyright © 2013 Elsevier Inc. All rights reserved. FIGURE 72.5 Bone mineral density (BMD) change in the calcium-treated and placebo groups (panel A) and by tertile of protein intake for the calcium-treated group (panel B) in the study of Dawson-Hughes et al. [28]. Source: Copyright Robert P. Heaney, Reproduced with permission. 6

Copyright © 2013 Elsevier Inc. All rights reserved. FIGURE 72.6 Slope of calcium balance on calcium intake derived from metabolic balance studies in 640 healthy women at mid-life [31]. Panel A is the slope for the entire group, irrespective of protein intake, and panel B shows the two slopes derived when the group is split at the median protein intake (62 g/day). Error bars are 1 standard error of the mean (SEM). Note that, for those with a protein intake below the median, the slope of calcium balance on calcium intake was not significantly different from zero. Source: Copyright Robert P. Heaney, Reproduced with permission. 7